Hélène M. Faessel

2.5k total citations
52 papers, 1.9k citations indexed

About

Hélène M. Faessel is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Physiology. According to data from OpenAlex, Hélène M. Faessel has authored 52 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 9 papers in Pulmonary and Respiratory Medicine and 9 papers in Physiology. Recurrent topics in Hélène M. Faessel's work include Ubiquitin and proteasome pathways (13 papers), Protein Degradation and Inhibitors (11 papers) and Smoking Behavior and Cessation (7 papers). Hélène M. Faessel is often cited by papers focused on Ubiquitin and proteasome pathways (13 papers), Protein Degradation and Inhibitors (11 papers) and Smoking Behavior and Cessation (7 papers). Hélène M. Faessel collaborates with scholars based in United States, Japan and United Kingdom. Hélène M. Faessel's co-authors include Aaron H. Burstein, Bruce J. Dezube, Patanjali Ravva, David J. Clark, Farhad Sedarati, Kathryn Williams, George Mulligan, Ronan Swords, Megan Gibbs and Harry P. Erba and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hélène M. Faessel

52 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hélène M. Faessel United States	23	1.1k	362	286	208	195	52	1.9k
Jun Wei China	31	1.8k 1.6×	501 1.4×	231 0.8×	134 0.6×	241 1.2×	169	3.6k
Liang Liu China	30	1.3k 1.1×	294 0.8×	80 0.3×	77 0.4×	130 0.7×	83	2.2k
Neil T. Thompson United Kingdom	24	956 0.8×	328 0.9×	154 0.5×	111 0.5×	192 1.0×	47	1.6k
Antonio Ardizzoia Italy	26	355 0.3×	710 2.0×	354 1.2×	63 0.3×	403 2.1×	77	2.1k
Ken‐ichi Fujita Japan	20	784 0.7×	420 1.2×	64 0.2×	146 0.7×	116 0.6×	53	1.9k
Edward Roberts United States	31	1.8k 1.6×	182 0.5×	257 0.9×	68 0.3×	107 0.5×	89	3.2k
Shuhei Suzuki Japan	26	1.1k 0.9×	509 1.4×	207 0.7×	19 0.1×	168 0.9×	116	2.0k
Dan Zhou China	20	1.3k 1.2×	408 1.1×	161 0.6×	74 0.4×	243 1.2×	57	2.3k
Xue Bai China	29	1.9k 1.6×	258 0.7×	239 0.8×	56 0.3×	219 1.1×	87	3.1k
Xavier Maréchal France	25	909 0.8×	261 0.7×	264 0.9×	59 0.3×	118 0.6×	55	2.0k

Countries citing papers authored by Hélène M. Faessel

Since Specialization

Citations

This map shows the geographic impact of Hélène M. Faessel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hélène M. Faessel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hélène M. Faessel more than expected).

Fields of papers citing papers by Hélène M. Faessel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hélène M. Faessel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hélène M. Faessel. The network helps show where Hélène M. Faessel may publish in the future.

Co-authorship network of co-authors of Hélène M. Faessel

This figure shows the co-authorship network connecting the top 25 collaborators of Hélène M. Faessel. A scholar is included among the top collaborators of Hélène M. Faessel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hélène M. Faessel. Hélène M. Faessel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Evans, Rebecca, Haruhide Kimura, Masato Nakashima, et al.. (2023). Orexin 2 receptor‐selective agonist danavorexton (TAK‐925) promotes wakefulness in non‐human primates and healthy individuals. Journal of Sleep Research. 32(5). e13878–e13878. 16 indexed citations

Zhou, Xiaofei, Farhad Sedarati, Douglas V. Faller, et al.. (2020). Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. Investigational New Drugs. 39(2). 488–498. 19 indexed citations

Swords, Ronan, Steven Coutré, Michael B. Maris, et al.. (2018). Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 131(13). 1415–1424. 157 indexed citations

Swords, Ronan, Justin M. Watts, Harry P. Erba, et al.. (2017). Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood Cancer Journal. 7(2). e520–e520. 28 indexed citations

Swords, Ronan, Steven Coutré, Michael B. Maris, et al.. (2016). Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML). Blood. 128(22). 98–98. 7 indexed citations

Dearnaley, David P., Daniel R. Saltzstein, John E. Sylvester, et al.. (2016). Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC). Annals of Oncology. 27. vi249–vi249. 7 indexed citations

Shah, Jatin J., Andrzej Jakubowiak, Owen A. O’Connor, et al.. (2015). Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clinical Cancer Research. 22(1). 34–43. 162 indexed citations

Sarantopoulos, John, Geoffrey I. Shapiro, Roger B. Cohen, et al.. (2015). Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(4). 847–857. 139 indexed citations

Goldman, Jonathan H., Sabine Eckhardt, Mitesh J. Borad, et al.. (2014). Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 21(5). 1002–1009. 43 indexed citations

10.

Ravva, Patanjali, Marc R. Gastonguay, Hélène M. Faessel, Theodore C. Lee, & Raymond Niaura. (2014). Pharmacokinetic-Pharmacodynamic Modeling of the Effect of Varenicline on Nicotine Craving in Adult Smokers. Nicotine & Tobacco Research. 17(1). 106–113. 11 indexed citations

11.

Ravva, Patanjali, Marc R. Gastonguay, Jonathan French, Thomas G. Tensfeldt, & Hélène M. Faessel. (2010). Quantitative Assessment of Exposure–Response Relationships for the Efficacy and Tolerability of Varenicline for Smoking Cessation. Clinical Pharmacology & Therapeutics. 87(3). 336–344. 18 indexed citations

12.

Ravva, Patanjali, Marc R. Gastonguay, Thomas G. Tensfeldt, & Hélène M. Faessel. (2009). Population pharmacokinetic analysis of varenicline in adult smokers. British Journal of Clinical Pharmacology. 68(5). 669–681. 46 indexed citations

13.

Faessel, Hélène M., Patanjali Ravva, & Kathryn Williams. (2009). Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics. 31(1). 177–189. 50 indexed citations

14.

Faessel, Hélène M., et al.. (2006). Single‐Dose Pharmacokinetics of Varenicline, a Selective Nicotinic Receptor Partial Agonist, in Healthy Smokers and Nonsmokers. The Journal of Clinical Pharmacology. 46(9). 991–998. 86 indexed citations

15.

Faessel, Hélène M., et al.. (2006). Multiple‐Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Smokers. The Journal of Clinical Pharmacology. 46(12). 1439–1448. 74 indexed citations

16.

Burstein, Aaron H., Terence Fullerton, David J. Clark, & Hélène M. Faessel. (2006). Pharmacokinetics, Safety, and Tolerability After Single and Multiple Oral Doses of Varenicline in Elderly Smokers. The Journal of Clinical Pharmacology. 46(11). 1234–1240. 44 indexed citations

17.

Müller, Ulrich, John Suckling, Fernando Zelaya, et al.. (2005). Plasma level-dependent effects of methylphenidate on task-related functional magnetic resonance imaging signal changes. Psychopharmacology. 180(4). 624–633. 38 indexed citations

18.

Faessel, Hélène M., et al.. (1999). Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-Amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin-6-yl)-(S)-ethyl]-2,5-thienoylamino-l-glutamic acid (AG2034). Biochemical Pharmacology. 57(5). 567–577. 11 indexed citations

19.

Faessel, Hélène M., et al.. (1998). Implications for Clinical Pharmacodynamic Studies of the Statistical Characterization of an In Vitro Antiproliferation Assay. Journal of Pharmacokinetics and Biopharmaceutics. 26(6). 717–733. 9 indexed citations

20.

Faessel, Hélène M., J.M. Scherrmann, Pascal Houzé, & Frédéric J. Baud. (1995). 4-Methylpyrazole monitoring during haemodialysis of ethylene glycol intoxicated patients. European Journal of Clinical Pharmacology. 49(3). 211–3. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact